Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gerlach

Showing results (231-240 of 352) with videos related to

Pageof 36
Sort By:
Der Anaesthesist|May 1, 1986
[Spasticity treatment with spinal morphine or midazolam. In vitro experiments, animal studies and clinical studies on compatibility and effectiveness]H Müller, H Gerlach, J Boldt, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 1982
Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibitionA L Barry, R N Jones, C Thornsberry, et al.
Gene|October 31, 1998
Structural organization of the human TOP2A and TOP2B genesA J Lang, S E Mirski, H J Cummings, et al.
Journal of Clinical Microbiology|January 1, 1989
Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory StandardsA L Barry, P C Fuchs, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1980
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycinR N Jones, P C Fuchs, H M Sommers, et al.
British Journal of Cancer|August 1, 1991
Tumourigenic multidrug-resistant HT1080 cells do not overexpress receptors for epidermal growth factorM L Slovak, S E Mirski, S P Cole, et al.
Journal of Chemotherapy (Florence, Italy)|October 1, 1993
In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centersH S Sader, R N Jones, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|September 1, 1992
Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheaeR N Jones, M E Erwin, J A Washington, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1991
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centersR N Jones, M A Pfaller, S D Allen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 1, 1992
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactamM A Pfaller, A L Barry, P C Fuchs, et al.
Pageof 36

Showing results (231-240 of 352) with videos related to

Sort By:
Pageof 36
Der Anaesthesist|May 1, 1986
[Spasticity treatment with spinal morphine or midazolam. In vitro experiments, animal studies and clinical studies on compatibility and effectiveness]H Müller, H Gerlach, J Boldt, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 1982
Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibitionA L Barry, R N Jones, C Thornsberry, et al.
Gene|October 31, 1998
Structural organization of the human TOP2A and TOP2B genesA J Lang, S E Mirski, H J Cummings, et al.
Journal of Clinical Microbiology|January 1, 1989
Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory StandardsA L Barry, P C Fuchs, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1980
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycinR N Jones, P C Fuchs, H M Sommers, et al.
British Journal of Cancer|August 1, 1991
Tumourigenic multidrug-resistant HT1080 cells do not overexpress receptors for epidermal growth factorM L Slovak, S E Mirski, S P Cole, et al.
Journal of Chemotherapy (Florence, Italy)|October 1, 1993
In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centersH S Sader, R N Jones, S D Allen, et al.
Diagnostic Microbiology and Infectious Disease|September 1, 1992
Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheaeR N Jones, M E Erwin, J A Washington, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1991
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centersR N Jones, M A Pfaller, S D Allen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 1, 1992
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactamM A Pfaller, A L Barry, P C Fuchs, et al.
Pageof 36